Key facts
- It has raised $1.6M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Shenzhen Capital Group, Beijing Mingfeng Capital, Hailiang Capital, Sunz Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Dr Heproa
- ·The full record, as it builds
Funding rounds
No funding rounds for Dr Heproa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dr Heproa
Manufacturer of bioactive formulations intended for dermatological and gut microbiome applications. The company offers immunological research, microecological skincare principles, and functional ingredient development, serving health-conscious consumers and clinical skincare markets to access targeted anti-aging solutions, probiotic-based wellness products, and skin barrier repair treatments through integrated product lines designed for early aging and sensitive skin conditions.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Shenzhen, China
- Founded
- 2020
- Website
- heproa.com/
- Ownership
- Privately Held (backing)
Dr Heproa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dr Heproa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dr Heproa in its N-PORT filings yet. We sweep new filings monthly.